

CLAIMS

1. A dermal and/or cosmetic galenic base whose aqueous phase contains at least two polyols each  
5 selected from the group comprising osides, oses and ose reduction products, characterized in that at least two of these polyols are selected from the group of ose reduction products comprising mannitol and xylitol.
- 10 2. The dermal and/or cosmetic galenic base as claimed in claim 1, characterized in that one polyol is selected from the group of oses comprising glucose, rhamnose, xylose, mannose and fructose.
- 15 3. The dermal and/or cosmetic galenic base as claimed in claim 1 or 2, characterized in that one polyol selected from the group of oses is rhamnose.
- 20 4. The dermal and/or cosmetic galenic base as claimed in claim 1, characterized in that one polyol is selected from the group of osides comprising fructooligosaccharides, the trisaccharide polymer of  $\alpha$ -L-fucose-1->3- $\alpha$ -D-galactose-1->3- $\alpha$ -D-galacturonic acid, hyaluronic acid, chondroitin sulfate, cyclodextrins,  
25 galactoarabinan and insulin.
5. A dermal and/or cosmetic galenic base whose fatty phase contains at least two liposoluble polyols each selected from the group comprising osides, oses, ose  
30 reduction products and chemically modified oses.
6. The galenic base as claimed in claim 5, characterized in that the chemically modified ose is selected from the group comprising Rhamnosoft®,  
35 cetearyl glucoside, mannitan laurate and glucose glutamate.
7. The dermal and/or cosmetic galenic base as claimed in any one of claims 1 to 4, characterized in that it

also contains a fatty phase comprising a substance selected from liporegulatory substances.

8. The dermal and/or cosmetic galenic base as claimed  
5 in claim 7, characterized in that the substance selected from liporegulatory substances is a lipid extract of *Laminaria ochroleuca* which is rich in eicosapentaenoic acid and docosa-hexaenoic acid.

10 9. The dermal and/or cosmetic galenic base as claimed in claim 7, characterized in that the substance selected from liporegulatory substances is soy oil.

10. The dermal and/or cosmetic galenic base as claimed  
15 in claim 7, characterized in that the substance selected from liporegulatory substances is linseed oil.

11. The dermal and/or cosmetic galenic base as claimed  
in claim 7, characterized in that the substance  
20 selected from liporegulatory substances is rapeseed oil.

12. The dermal and/or cosmetic galenic base as claimed  
in claim 7, characterized in that the substance  
25 selected from liporegulatory substances is a fish oil rich in alpha-linolenic, eicosapentaenoic and docosa-hexaenoic acids.

13. The dermal and/or cosmetic galenic base as claimed  
30 in claim 7, characterized in that the substance selected from liporegulatory substances is a product obtained by synthetic or biosynthetic chemistry of the mono-, di- or triglyceride type, or a phospholipid or glycolipid whose fatty acid composition is between 10  
35 and 100% of alpha-linolenic, eicosapentaenoic and docosa-hexaenoic acids.

14. The use of at least two polyols each selected from the group comprising osides, oses and ose reduction

products, characterized in that at least two of these polyols are selected from the group of ose reduction products comprising mannitol and xylitol, in the aqueous phase of a dermal and/or cosmetic galenic base, for improving its tolerability and/or optimizing the effect of at least one active ingredient.

15. The use as claimed in claim 14, characterized in that the polyol is selected from the group of oses comprising glucose, rhamnose, xylose, mannose and fructose.

14. The use as claimed in claim 14, characterized in that the polyol is selected from the group of oses is rhamnose.

15. The use as claimed in claim 14, characterized in that the polyol is selected from the group of osides comprising fructooligosaccharides, the trisaccharide polymer of  $\alpha$ -L-fucose-1->3- $\alpha$ -D-galactose-1->3- $\alpha$ -D-galacturonic acid, hyaluronic acid, chondroitin sulfate, cyclodextrins, galactoarabinan and insulin.

16. The use of at least two liposoluble polyols each selected from the group comprising osides, oses, ose reduction products and chemically modified oses, in the fatty phase of a dermal and/or cosmetic galenic base, for improving its tolerability and/or optimizing the effect of at least one active ingredient.

17. The use as claimed in claim 16, characterized in that the chemically modified ose is selected from the group comprising Rhamnosoft®, cetearyl glucoside, mannitan laurate and glucose glutamate.

18. The dermal and/or cosmetic galenic base as claimed in any one of claims 1 to 13, characterized in that the

total polyol content is between 0.1 and 40% of the total weight of the aqueous phase.

19. The dermal and/or cosmetic galenic base as claimed  
5 in either one of claims 5 and 6, characterized in that the total content of chemically modified ose is between 0.01 and 10% of the total weight of the fatty phase.
20. The dermal and/or cosmetic galenic base as claimed  
10 in either one of claims 7 and 13, characterized in that the total content of liporegulatory substances is between 0.01 and 100% of the total weight of the fatty phase.
- 15 21. A cosmetic and/or dermo-cosmetic composition, characterized in that it comprises a base as claimed in any one of claims 1 to 13 and 18 to 20.